Ebola Hemorrhagic Fever

A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS.

Also Known As:

Hemorrhagic Fever, Ebola; Ebola Infection; Ebola Virus Infection; Ebolavirus Infections; Infection, Ebola; Infection, Ebola Virus; Infection, Ebolavirus; Infections, Ebolavirus; Virus Infection, Ebola; Ebola Virus Disease; Ebolavirus Infection

Networked: 794 relevant articles (80 outcomes, 84 trials/studies)

Relationship Network

Disease Context: Research Results

Infections: 526564
- Virus Diseases: 41777
  - RNA Virus Infections: 303
    - Viral Hemorrhagic Fevers: 121
      - Ebola Hemorrhagic Fever: 794
    - Mononegavirales Infections: 1
      - Filoviridae Infections: 97
        Ebola Hemorrhagic Fever: 794

Related Diseases

1.	Infections
2.	Vesicular Stomatitis
3.	Ebola Hemorrhagic Fever
4.	COVID-19
5.	Neoplasms (Cancer)

Experts

1.	Feldmann, Heinz: 34 articles (12/2021 - 01/2002)
2.	Qiu, Xiangguo: 26 articles (12/2021 - 01/2012)
3.	Bavari, Sina: 24 articles (01/2021 - 07/2004)
4.	Geisbert, Thomas W: 21 articles (01/2022 - 03/2002)
5.	Hensley, Lisa E: 20 articles (01/2022 - 03/2002)
6.	Jahrling, Peter B: 20 articles (12/2019 - 03/2002)
7.	Dye, John M: 17 articles (01/2022 - 11/2005)
8.	Olinger, Gene G: 17 articles (01/2019 - 11/2005)
9.	Kawaoka, Yoshihiro: 16 articles (11/2020 - 01/2002)
10.	Becker, Stephan: 15 articles (04/2021 - 11/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ebola Hemorrhagic Fever:

1.	VaccinesIBA 01/01/2016 - "During the 2014 Ebola virus disease (EVD) outbreak, policy-makers were confronted with difficult decisions on how best to test the efficacy of EVD vaccines. " 07/01/2012 - "However, a number of vaccine candidates have been developed in the last decade that are highly protective in NHPs, the gold standard animal model for ebola hemorrhagic fever. " 08/15/2000 - "However, the complete protection achieved with active immunization with VRP, as well as the unique characteristics of the VEE replicon vector, warrant further testing of the safety and efficacy of NP-VRP and GP-VRP in primates as candidate vaccines against Ebola hemorrhagic fever." 10/01/2018 - "Despite significant progress in the characterization of vaccine-induced immunity, human correlates of protection against Ebolavirus infection have not yet been fully established. " 07/01/2015 - "Demonstration of vaccine or therapeutic efficacy in NHP models of ebolavirus infection is crucial to the development and eventual licensure of ebolavirus medical countermeasures, so that safe and effective countermeasures can be accelerated into human clinical trials. "
2.	Monoclonal AntibodiesIBA 07/01/2015 - "Most recently, a cocktail of monoclonal antibodies has been shown to be highly effective in protecting non-human primates from Ebola virus infection. " 01/01/2021 - "Monoclonal antibodies (mAbs) have proven effective for the treatment of ebolavirus infection in humans, with two mAb-based drugs Inmazeb™ and Ebanga™ receiving FDA approval in 2020. " 07/01/2013 - "Monoclonal antibodies (MAbs) are currently a promising treatment strategy against Ebola virus infection. " 01/01/2012 - "Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever." 01/01/2018 - "Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice."
3.	AntibodiesIBA 05/01/2013 - "Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever?" 01/01/2023 - "In Guinea, serological tests have shown the absence of antibodies in people declared cured of Ebola Virus Disease (EVD), thus refuting their previous diagnosis; and the presence of antibodies in contact cases who had not been diagnosed. " 05/01/2001 - "Thus antibodies suppress or delay viral growth, provide protection against lethal Ebola virus infection, and may not require participation of other immune components for protection." 09/16/2021 - "The 2013-2016 Ebola epidemic in West Africa provided large survivor cohorts spurring a large number of human studies which showed that specific neutralising antibodies played a key role in protection following a natural Ebola virus infection, as part of the overall humoral response and in conjunction with the cellular adaptive response. " 01/01/2020 - "Our study expands the list of candidate antibodies and the options for successfully treating ebolavirus infection."
4.	Ebola VaccinesIBA 02/01/2015 - "In addition, the development of animal models for efficacy evaluation of Ebola vaccines and the mechanism of immune protection against Ebola virus infection are also discussed. " 09/01/2014 - "While ebolavirus vaccines have been proposed as an intervention to protect apes, their effectiveness would be improved if we could diagnostically confirm Ebola virus disease (EVD) as the cause of die-offs, establish ebolavirus geographical distribution, identify immunologically naïve populations, and determine whether apes survive virus exposure. " 01/01/2017 - "Each of the three Ebola virus disease-affected countries, Sierra Leone, Guinea, and Liberia, conducted a phase II/III Ebola virus vaccine trial. " 01/01/2017 - "Declining incidence and spatial heterogeneity complicated the design of phase 3 Ebola vaccine trials during the tail of the 2013-16 Ebola virus disease (EVD) epidemic in West Africa. " 01/01/2019 - "Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. "
5.	Glycoproteins (Glycoprotein)IBA 11/22/2018 - "Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs." 11/13/2023 - "This case study investigated the long-term expression dynamics of Ebola virus (EBOV) soluble glycoprotein (sGP) in the serum of a patient who was infected with EBOV in West Africa and recovered from acute Ebola virus disease (EVD) at the National Institutes of Health Clinical Center in Bethesda, Maryland. " 01/01/2021 - "Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR." 11/13/2018 - "Here, we engineer DMAbs encoding potent anti-Zaire ebolavirus (EBOV) glycoprotein (GP) mAbs isolated from Ebola virus disease survivors. " 10/01/2018 - "Several mutations in the fusion loop were substitutions of residues present in other ebolavirus glycoproteins, illustrating the evolutionary paths for maintaining an optimally functioning fusion loop under selection pressure.IMPORTANCEZaire ebolavirus (EBOV) is the causative agent of the highly lethal Ebola virus disease and poses a significant threat to the global health community. "
6.	ZMappIBA 12/15/2016 - "Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection." 01/01/2017 - "Trial of ZMapp for Ebola Virus Infection." 01/01/2017 - "Trial of ZMapp for Ebola Virus Infection." 10/13/2016 - "A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection." 10/02/2014 - "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp."
7.	Antiviral Agents (Antivirals)IBA 01/01/2023 - "Characterization of an air-liquid interface primary human vaginal epithelium to study Ebola virus infection and testing of antivirals." 01/01/2015 - "These studies provide new potential avenues for antiviral targeting as these genes that have not previously appreciated to inhibit negative strand RNA viruses and specifically Ebola virus infection. " 11/15/2023 - "An Antiviral Role for TRIM14 in Ebola Virus Infection." 09/30/2023 - "Novel Antiviral Molecules against Ebola Virus Infection." 11/01/2022 - "Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. "
8.	remdesivirIBA 01/01/2021 - "Remdesivir is the drug of choice for Ebola virus disease and has been authorized for emergency use. " 01/01/2020 - "Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. " 01/01/2022 - "Remdesivir was originally developed to treat Ebola hemorrhagic fever, and its efficacy in treating coronavirus disease 2019 was detected during a preliminary analysis of a randomized controlled trial. " 11/01/2020 - "Remdesivir: A beacon of hope from Ebola virus disease to COVID-19." 01/01/2021 - "Remdesivir (GS-5734), a drug initially developed to treat hepatitis C and Ebola virus disease, was the first approved treatment for severe coronavirus disease 2019 (COVID-19). "
9.	Neutralizing AntibodiesIBA 01/22/2007 - "Protective efficacy of neutralizing antibodies against Ebola virus infection." 11/05/2018 - "Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors." 03/18/2016 - "Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody." 01/28/2016 - "Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection." 10/01/2015 - "Importantly, #3327 is able to block entry of virions bearing GP that contain the Q508 escape mutation common to a number of virus-neutralizing antibodies, and therefore provides future perspectives for treatment strategies against Ebola virus infection. "
10.	RNA (Ribonucleic Acid)IBA 01/01/2017 - "Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study." 07/01/2023 - "We assessed rates of livebirths and other pregnancy results in both study groups, and presence of Ebola RNA by PCR in samples of placenta, maternal and cord blood, breastmilk, and vaginal secretions from people who had recovered from Ebola who conceived a median of 14 months after acute Ebola virus disease. " 01/01/2017 - "Recent studies have suggested that Ebola virus (EBOV) ribonucleic acid (RNA) potentially present in the semen of a large number of survivors of Ebola virus disease (EVD) in Western Africa may contribute to sexual transmission of EVD and generate new clusters of cases in regions previously declared EVD-free. " 01/01/2016 - "In this study, we analyze RNA sequencing data to determine the host response to Ebola virus infection in circulating immune cells. " 01/01/2021 - "Ebola virus RNA can reside for months or years in semen of survivors of Ebola virus disease and is probably associated with increased risk for cryptic sexual transmission of the virus. "

Therapies and Procedures

1.	Therapeutics 12/12/2019 - "Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial. " 01/01/2020 - "Antibody-based therapies are a promising treatment option for managing ebolavirus infections. " 02/01/2017 - "Improved therapies are required to reduce mortality risk in Ebola virus disease. " 11/13/2023 - "This study identified novel mAbs that were elicited through immunization and able to provide protection from ebolavirus infection, thus enriching the pool of candidate therapeutics for treating Ebola disease." 01/01/2023 - "We conduct simulation studies to evaluate the performance of the proposed method and provide illustration examples based on trials of Ebola virus disease therapeutics and hemostat in vascular surgery."
2.	Critical Care (Surgical Intensive Care) 02/01/2018 - "Ebola virus disease: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine." 01/01/2018 - "Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa." 02/01/2017 - "[Intensive care treatment of a patient with Ebola virus disease in Germany]." 05/01/2016 - "Ebola virus disease: the UK critical care perspective." 12/01/2015 - "Lessons for pulmonary critical care from treatment of Ebola virus disease in developed countries."
3.	Renal Replacement Therapy (Therapies, Renal Replacement) 01/01/2015 - "Minimizing risks associated with renal replacement therapy in patients with Ebola virus disease." 01/01/2014 - "Preparing for renal replacement therapy in patients with the Ebola virus disease." 10/01/2015 - "In the severe form, patients with Ebola virus disease may require life-sustaining therapy, including mechanical ventilation and renal replacement therapy. " 10/01/2015 - "The patients received mechanical ventilation, renal replacement therapy, invasive monitoring, vasopressor support, and investigational therapies for Ebola virus disease. " 01/01/2014 - "The Ebola virus disease (EVD) is a serious illness characterized by fever, severe vomiting and diarrhea, and, in severe cases, multi-organ failure requiring mechanical ventilation and renal replacement therapy. "
4.	Intramuscular Injections 01/01/2023 - "In non-human primates, immunological memory was also formed as shown by an anamnestic response after high-dose, intramuscular injection with Ebola virus, but was not sufficient for protection against Ebola virus disease at later timepoints due to a decline in circulating antibodies and the fast kinetics of disease in the non-human primates model. "
5.	Hand Hygiene 06/01/2017 - "The study assessed hand hygiene practices for infection control after the West African Ebola virus disease outbreak in a Nigerian teaching hospital. " 01/01/2021 - "During the 2014-2016 West Africa Ebola virus disease epidemic in Liberia, gaps in hand hygiene infrastructure and health worker training contributed to hospital-based Ebola transmission. " 07/01/2019 - "Hand hygiene practices in the context of Ebola virus disease: A cross-sectional survey of Lagos residents." 06/01/2017 - "HAND HYGIENE PRACTICES POST EBOLA VIRUS DISEASE OUTBREAK IN A NIGERIAN TEACHING HOSPITAL." 06/01/2017 - "Ebola virus disease (EVD) is a highly contagious viral infection that requires a high risk perception and practice of good hand hygiene by regular hand washing or use of hand sanitizers for infection control at all time. "